ClinicalTrials.gg
Enrolling by invitationNCT07083115Updated Mar 23, 2026

Developing MRI Technologies for Atrial Fibrillation

An observational study in Atrial Fibrillation (AF), sponsored by The Cleveland Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by The Cleveland Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Atrial Fibrillation by The Cleveland Clinic — 10 open to participants now, 11 under way, 1 of them phase 3. Atrial Fibrillation · The Cleveland Clinic.

Planned enrollment
9th of 13
50 · median 60
Started
2025
with 3 others
Observational
13 of 26
5 open now
Primary completion
2027-09
later than 2 of 10 live
Registered
23rd of 26
by date

Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 23rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

10 of the 26 studies in Atrial Fibrillation by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Atrial Fibrillation by The Cleveland Clinic, or all of them as a file.
02

Study summary

To measure image quality of damaged areas of the heart in patients with Atrial fibrillation using the contrast Gadopiclenol vs conventional Gadolinium-based contrast agents(GBCA)

Read the detailed description

With the use of gadolinium-based contrast agents (GBCA), cardiac MRI has become the clinical gold standard in tissue characterization of fibrosis in the ventricular myocardium. More recently, contrast enhanced cardiac MRI using standard class I GBCA was proposed to reveal fibrosis in the left atrium to characterize AF via the DECAF and DECAF II studies.

Unfortunately, the results were negative with the culprit reason being the lack of clear visualization of the enhanced regions. This claim was substantiated in a recent 2024 Langendorff (reanimated ex vivo) human heart study in AF patients showing clearly the presence of fibrosis with microscopy and more importantly it showed contrast enhanced MRI can also visualize the fibrosis an equivalent 4x dose of GBCA. However, the study was performed ex vivo and no follow up in vivo study was performed to test the in vivo viability. Thus the investigators propose the unique use of standard dose of Gadopiclenol (Elucerim), a novel high relaxivity agent, contrast enhanced MRI to scan AF patients to identify and characterize areas of fibrosis and validate the electrophysiology dysfunction in those same regions.

It is hypothesized that the Gadopiclenol can provide an improved enhancement as compared to the use of conventional GBCA like Gadovist and potentially can better reveal the AF fibrotic infiltrate. Furthermore, the higher contrast to noise ratio (CNR) of the lesion will support a significantly higher spatial resolution and potentially enable sub-mm high resolution imaging.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • Cardiac MRI
  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients screened for atrial fibrillation from established afib clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Diagnosis of Atrial Fibrillation

Exclusion criteria

Exclusion Criteria:

  • to MRI
  • Contraindications to Gadolinium based contrast agents.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Image quality

    To demonstrate standard dose (0.05mmol/kg) of Gadopiclenol cardiac MRI significantly improves the enhancement of AF compared with standard dose (0.1mmol/kg) of conventional GBCA agents. Research MRI data will be reviewed against any standard clinical MRI available in the patient's medical record.

    Time frame: At completion of each MRI

Secondary outcomes

  1. High resolution Cardiac MRI for improved imaging of AF

    To demonstrate standard dose (0.05mmol/kg) of Gadopiclenol can enable ultra-high resolution sub-mm cardiac 3D MRI scan for significantly improved imaging of AF. AF patients (N=100), will be recalled for a research scan using the proposed Gadopiclenol contrast agent. The research scan will use a novel 0.9 mm isotropic 3D LGE scan. Wall sharpness measured in units of (1/mm) and lesion CNR will be calculated for both scans and compared. Scan time for both sequences will be made equal. The primary outcome is in Aim 1 of comparing Gadopiclenol cardiac MRI scans with conventional GBCA cardiac MRI in the context of LA enhancement via contrast to noise ratio (CNR). Previous work in our group using a standard dose of GBCA in RF ablated pigs shows an effect size of about 1.0 in CNR between Gadopiclenol and conventional GBCA in LV enhancement. Assuming this effect size, 80% statistical power, and an alpha = 0.5, it would require at least 32 subjects.

    Time frame: At completion of each MRI

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 32 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Jan 16, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07083115
Collaborators
Guerbet
Responsible party
Christopher Nguyen (Director of Cardiovascular Innovation Research Center, The Cleveland Clinic) — Principal investigator
First posted
Jul 24, 2025
Start date
Jan 16, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 23, 2026

Study contacts

Christopher Nguyen, PhD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion